世衛若沒提供科興疫苗的評估報告, 老韭們大概只能寄望中國藥廠生產的俄羅斯疫苗了~
"The Russian Direct Investment Fund, which has been in charge of international cooperation for Sputnik V, said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxin Gene tech Co.
The two deals are in addition to a deal announced last November with Tibet Rhodiola Pharmaceutical Holding Co, which had paid $9 million to manufacture and sell the Sputnik V vaccine in China. RDIF said in April the terms of the deal were for 100 million doses with a subsidiary company belonging to Tibet Rhodiola."
"However, none of the three Chinese companies has begun manufacturing Sputnik V as of yet."
結果親中的新加坡宣布打科興疫苗者不計入疫苗接種人數內....
"Both have shown efficacy rates of well over 90% against symptomatic disease in clinical trials, compared with trials for Sinovac that shown results from as low as 51% to about 84%."
泰國這研究等於是說打科興者在兩個月後回到接種前⋯
「曼谷郵報（Bangkok Post）報導，這份研究是由泰國法政大學（Thammasat University）以及國家基因工程與生物技術中心（National Centre for Genetic Engineering and Biotechnology ）共同完成。
這份研究由國家基因工程與生物技術中心轄下的研究團隊主任安南（Anan Jongkaewwattan）在臉書上公布結果。
安南指出，他們研究了500個接受2劑科興疫苗的民眾，發現每40天民眾體內的抗體就減少50%，第一劑和第二劑間隔超過60天的人，抗體會低於第一劑和第二劑間隔在60天以內的人。」
繼泰國之後，香港的比較結果也出來了:
"港大研究人員從公私立醫院和診所徵求1442名醫護人員展開實驗，從不同時間點採集血液樣本，結果在第1批93名受試者當中，發現63名BNT接種者在第1劑和第2劑後體內抗體都大幅上升，但30名科興接種者的第1劑抗體濃度為「低」，第2劑才達到中等。
另外，施打BNT的受試者，其體內抗體數值為269，比科興疫苗的27足足高出20倍左右。研究人員還發現，抗體濃度最低的BNT施打者，仍然比最高的科興接種者還要多。"
韓國媒體的報導比較直率:
[ 印度尼西亚的日确诊患者5月中旬达到2000多人，但从6月21日开始，每天确诊患者超过1.5万人，这次是首次日确诊人数超过5万人。这相当于当天全世界55.4419万名新增确诊患者中约有10%发生在印度尼西亚。美国CNN15日报道称，“印度尼西亚将超过印度，成为新的新冠震源”。
在印度尼西亚，接种第一针疫苗的比率为13.3%，接种第二针疫苗的比率仅为5.5%。问题在于在印度尼西亚接种的疫苗中，90%都是曾引发“水疫苗”争议的中国产科兴疫苗。]
https://cnnews.chosun.com/client/news/viw.asp?nNewsNumb=20210755658&cate=C01&mcate=M1001
現實主義的印馬泰如果都對科興效果沒有信心，接下來翻盤的國家會更多。
"《BBC中文網》報導，泰國上週宣布改變接種策略，從原先注射兩劑科興疫苗，改為一劑科興加上一劑AZ疫苗，印尼上週也宣布，將給接種科興疫苗的醫護人員施打莫德納加強劑，世衛疫情警報負責人費雪（Dale Fisher）認為，此舉代表泰國和印尼對疫苗失效感到擔憂。
除了泰國和印尼，馬來西亞也宣布打完科興後，將改打輝瑞疫苗，而菲律賓和柬埔寨則選擇繼續沿用中國疫苗，對此科興尚未回應。"
希望世界各國不要用到效果差、價格高的中國疫苗。（合什
「和COVAX合作、主要为全球发展中国家取得疫苗的全球疫苗免疫联盟Gavi近来就宣布，已和中国国药集团（Sinopharm）与科兴公司（Sinovac）签署采购协定，这两家已经得到世界卫生组织紧急授权认证的中国制灭活疫苗，将在今年第三季共交货1亿1000万剂，Gavi还计划，如有需要，预计到2022年上半年，将采购中国疫苗共约5亿5000万剂。⋯
⋯ 专注生技制药行业的美国网站BioSpace日前报道，中国科兴疫苗（Sinovac Biotech）每剂要价29.75美元；比辉瑞的19.5美元要贵逾10美元。本台无法独立证实上述数据。若照此计算，科兴今年第三季与Gavi签署的5000万剂采购合约，将有15亿美元的营收入帐。」
https://www.rfa.org/mandarin/yataibaodao/huanjing/rc-07202021122013.html
🤣 🤣 🤣 🤣
"從出爐的證據看
Omicron的死亡率比科興低
防護力比科興高"
https://www.facebook.com/MASTEROFTT/photos/a.113161687771059/143164334770794/
南華早報的原文連結:
"The researchers also found that the BioNTech recipient with the lowest level of antibodies still had more than the Sinovac taker with the highest.
Sinovac-generated antibody levels were judged to be about the same as, or slightly lower than, those detected in recovered Covid-19 patients."
@Perfume 我相信這不是joke
各家疫苗對變異株的防護效果會是下半年的評估重點:
"Sinovac and Sinopharm are studying the protection the vaccines provide against the Delta variant, but haven’t released any data yet. Both companies have said a booster shot may be needed at some point after their two-dose regimens.
Two recent studies in the U.K. determined that vaccines made by Pfizer and AstraZeneca are highly effective at preventing severe illness caused by the variant, while their overall protection against infection may be reduced. A separate study of the Pfizer vaccine conducted in Israel showed similar outcomes."
https://www.wsj.com/articles/countries-signal-doubts-about-delta-protection-from-chinese-vaccine-11626183948?st=rc1gl94mmof07ya&reflink=desktopwebshare_permalink